Adamis Pharmaceuticals (NASDAQ:ADMP) had its price target hoisted by analysts at B. Riley from $6.25 to $7.50 in a research report issued on Friday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. B. Riley’s target price suggests a potential upside of 114.29% from the company’s previous close.
Several other equities research analysts have also issued reports on the company. Maxim Group set a $5.00 price target on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, February 14th. ValuEngine lowered Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, November 30th. Zacks Investment Research raised Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Finally, Raymond James Financial set a $7.00 price target on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, February 23rd. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. Adamis Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $6.50.
Shares of Adamis Pharmaceuticals (NASDAQ ADMP) opened at $3.50 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.44 and a quick ratio of 3.79. Adamis Pharmaceuticals has a 52 week low of $2.35 and a 52 week high of $6.45.
ILLEGAL ACTIVITY NOTICE: “Adamis Pharmaceuticals (ADMP) PT Raised to $7.50” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3298470/adamis-pharmaceuticals-admp-pt-raised-to-7-50.html.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.